NEW YORK (GenomeWeb) – Editas Medicine will offer 5.9 million shares of common stock in its planned initial public offering, at a price of $16 per share, according to a document filed today with the US Securities and Exchange Commission.

The Cambridge, Massachusetts-based firm said it expects to raise $94.4 million — $87.8 million in proceeds after discounts and commissions to the underwriters.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.

Sep
12
Sponsored by
PerkinElmer

This webinar will cover recent advances in the use of CRISPR for generating animal models and cell lines.